vCISO · Digital health & life sciences
Virtual CISO for Biotech & Pharma Companies
A vCISO gives a lean biotech or pharma company executive-level security leadership the moment its most valuable asset — unfiled science — needs a defensible story, without the cost of a full-time hire. Engagements typically start when a licensing partner's diligence team asks pointed questions a thirty-person company has nobody designated to answer, or when lab, GxP and corporate networks have grown together with no segmentation plan. The vCISO builds the risk assessment, the roadmap and the program a partner, an inspector or an insurer will actually accept.
Reviewed by the Privacy Horizon team · Last reviewed
What you're protecting
What a vCISO has to protect in a lean biotech or pharma company
The environment a vCISO inherits is small in headcount and enormous in what a single failure could cost, so scope has to be set deliberately rather than left to whatever grew organically.
Unfiled pipeline IP
Sequences, synthesis routes and dossiers that carry the company's entire valuation, requiring access controls and monitoring that most fifteen-person teams have never had to design.
Lab and GxP-adjacent instrument networks
LIMS, ELN and connected lab instruments frequently sitting on the same flat network as email and finance, with no segmentation between research and corporate traffic.
The sponsor's oversight of trial and PSP data
Even where a CRO or hub vendor operates the systems day to day, the vCISO has to know where that identifiable layer lives and what happens if the vendor is compromised.
Founder and executive credentials ahead of a raise
Accounts holding cap table, term sheet and deal-room access become higher-value targets in the months before a financing or licensing announcement, not lower-value ones.
A vendor ecosystem the company didn't design
CROs, hub vendors, central labs and cloud platforms accumulate faster than internal security oversight does in a company this size, leaving gaps nobody has mapped.
Regulatory map
Why licensing partners and inspectors expect a named security leader
A company without anyone accountable for security is itself a finding, long before an auditor looks at a single control.
PIPEDA's accountability principle
Canadian privacy law expects an organization to designate someone responsible for compliance; a biotech with no such person is answering a diligence questionnaire from a position of weakness before the first question is asked.
Division 5 sponsor obligations
Health Canada's GxP inspection programs expect the computerised systems behind a trial to have a named, responsible owner, not an arrangement nobody in the company could actually describe.
Cyber-insurance underwriting on IP exposure
Renewal applications increasingly ask how unfiled research is segmented and who owns that decision, and 'nobody, formally' is an answer that raises premiums or limits coverage.
What goes wrong
What a vCISO's program is built to catch in this environment
The threats that matter most here rarely resemble a generic ransomware note; they target the two things a small biotech cannot easily replace.
IP theft aimed at research and manufacturing know-how
Sophisticated and state-linked actors go after synthesis routes and process documentation specifically, because unfiled science is worth more undisclosed than any ransom a criminal group could demand.
Compromise at a CRO or PSP hub vendor
A breach outside the company's own walls can still expose the identifiable layer of trial or patient-program data the sponsor is ultimately answerable for.
Lateral movement from lab to corporate systems
An unsegmented instrument network turns a compromised sequencer or lab laptop into a path toward finance, email and the deal room, rather than an isolated incident.
Manufacturing OT disruption
Ransomware reaching operational technology on a production floor can halt GMP-controlled manufacturing entirely, a business-continuity risk few early security programs are built to address.
Our vciso for biotech & pharma companies
What our vCISO service covers for a biotech or pharma company
The same four pillars our vCISO service always delivers, scoped specifically to pipeline IP, trial oversight and a lean team's realistic capacity.
Risk assessment across IP, lab and vendor systems
A clear picture of where pipeline IP, lab instrument networks and third-party trial or PSP vendors carry the most exposure, in language a board or a partner can follow.
A roadmap built around your deal calendar
A prioritized security plan sequenced against financing rounds and partnering conversations, so the work that matters for the next diligence review happens first.
Network segmentation and policy execution
Hands-on support separating lab and GxP-adjacent systems from the corporate domain, and formalizing the access-control and IP-handling policies a small team has never had to write.
Ongoing oversight through growth and audits
Continued tracking of the security program as headcount, vendors and systems change, so the story a vCISO tells a partner today still holds up at the next review.
How the engagement runs
How a vCISO engagement runs for a lean biotech or pharma team
Scoped around what the company actually has — a small team, a few critical systems, and a deal timeline that won't wait.
Step 1
Map the environment
We inventory pipeline IP, lab and GxP-adjacent systems, and the CROs, hubs and cloud vendors touching trial or PSP data, and score where the real exposure sits.
Step 2
Build the roadmap
Findings become a prioritized plan sequenced against your financing or licensing calendar, so effort lands where the next diligence review will look first.
Step 3
Execute the priority work
Segmentation, access controls and policy documents are put in place with your team doing the implementation and ours directing it.
Step 4
Maintain the program
Ongoing oversight keeps the roadmap current as headcount and vendors change, so the security story stays defensible between one review and the next.
What it costs
What drives vCISO cost for a biotech or pharma company
Cost depends on how many systems actually touch pipeline IP or trial oversight, how many CRO, hub and lab vendors need to be mapped into the risk picture, and how tight your financing or licensing timeline is. A fifteen-person discovery biotech with one lab and no active trial costs less to assess than a clinical-stage company juggling multiple CRO relationships and a live PSP.
Engagements typically scale from a focused risk assessment ahead of a single diligence event to ongoing fractional leadership through a full financing cycle. We scope pricing after an initial review of your systems and deal calendar rather than quoting a flat rate.
Biotech & Pharma Companies: vCISO questions, answered
Start by identifying exactly which systems hold the unfiled science that matters most, then apply access controls and monitoring to that narrow set before spreading effort across everything else. A vCISO does this scoping work directly, so a small team gets protection sized to what actually needs it rather than a generic program built for a much larger organization.
They expect evidence that someone owns security decisions, that pipeline IP is segmented from general corporate access, and that trial or PSP data flowing to your vendors has been reviewed, not assumed to be fine. A named vCISO with a documented risk assessment and roadmap answers all three before the diligence team has to ask.
Segmentation does not require replacing existing lab equipment or GxP-validated systems; it usually means adding network boundaries, tightening access rules, and separating administrative credentials from research ones. A vCISO prioritizes the highest-risk boundary first — typically between instrument networks and general corporate IT — rather than attempting a full rebuild at once.
For most companies at this stage, yes, at least until headcount and system complexity justify a full-time role. A vCISO provides executive-level judgment on a fractional basis, which is usually enough to satisfy partners and inspectors long before an internal hire becomes the more economical option.
Yes. Most engagements ahead of a specific deal start with a focused risk assessment scoped to what the diligence team is likely to ask about, which can be turned around faster than a full program build. The roadmap and ongoing oversight typically follow once the immediate deadline is met.
A vCISO owns security architecture and technical risk — network segmentation, access controls, incident readiness — while a VPO owns privacy accountability and regulatory obligations such as PSP consent and breach notification. Many biotechs run both roles together, since the two functions answer different halves of the same diligence questionnaire.
More for biotech & pharma companies
Other services for this niche
- Privacy & security for biotech & pharma companies — overview
- Virtual Privacy Officer
- Penetration Testing
- Incident Response Planning
- Privacy & Security Policy Development
- Privacy & Security Training
- Vendor Security Review & Questionnaire Support
- ISO 27001 Readiness
- HIPAA Readiness
- M&A Privacy & Security Due Diligence
About this service
What's Protecting Your Business from the Next Threat?
Don't wait for a breach to expose your vulnerabilities. Let Privacy Horizon secure your data, ensure compliance, and build lasting trust.